Token导航 LogoToken导航TokenDH.com
研究检索权限需确认github未标认证来源可访问许可证需确认审计提醒

tooluniverse-variant-functional-annotationtooluniverse 变体功能注释

Agent Skill

tooluniverse-variant-functional-annotation 用于查找、检索和筛选相关信息,适合在 Codex、Claude、Cursor、Gemini CLI 中需要根据关键词、任务场景或来源线索快速定位候选结果时使用。可结合来源仓库、安装命令和原始 README 继续核验具体用法。安装前建议确认权限范围、维护状态,以及是否会触发联网、命令执行或文件读写。

总安装

1,098

周安装

44

GitHub Stars

1,315

下载量

356
CodexClaudeCursorGemini CLI

安装说明

本站只整理中文说明和来源信息,不托管安装包,也不代用户安装。

GitHub

来源数

2

许可证

unknown

最后核验

2026-05-01

来源状态

来源可访问

安装方式

通过对话安装

复制提示词发给支持本地命令或 Skills 的 AI 助手,先确认命令和权限,再让它执行。

请帮我安装这个 Agent Skill:tooluniverse-variant-functional-annotation(tooluniverse 变体功能注释)
来源仓库:https://github.com/mims-harvard/tooluniverse
仓库路径:skills/tooluniverse-variant-functional-annotation
安装命令:
npx skills add https://github.com/mims-harvard/tooluniverse --skill tooluniverse-variant-functional-annotation
安装前请先检查当前环境是否支持对应 CLI,并向我确认将要执行的命令、安装目录、联网范围和文件读写权限;确认后再执行。

命令行安装

复制命令到本机终端执行。该命令会通过 npx skills 从第三方来源获取 Skill;本站只展示命令,不托管安装包,也不自动执行。

skills.shnpx skills
npx skills add https://github.com/mims-harvard/tooluniverse --skill tooluniverse-variant-functional-annotation

简介

用于查找、检索和筛选变体功能注释相关信息。

  • 适合在 Codex、Claude、Cursor、Gemini CLI 中根据关键词快速定位候选结果。
  • 通过 npx 命令从 GitHub 仓库安装并使用。
  • 安装前需确认权限范围和维护状态,注意可能触发联网或文件操作。
  • tooluniverse-variant-functional-annotation 属于研究检索类 Skill,可作为该场景下的辅助能力补充。

SKILL.md

Protein Variant Functional Annotation

Comprehensive functional annotation of protein variants by combining ProtVar structural/functional context, ClinVar clinical classifications, gnomAD population frequencies, CADD deleteriousness scoring, and ClinGen gene-disease validity.

Differentiation from tooluniverse-variant-interpretation: This skill focuses specifically on protein-level functional evidence — structural mapping, residue context, protein domain impact, and population allele frequencies. It does NOT produce full ACMG classifications or treatment recommendations. Use tooluniverse-variant-interpretation for complete ACMG clinical classification.

LOOK UP, DON'T GUESS

When uncertain about any scientific fact, SEARCH databases first (PubMed, UniProt, ChEMBL, ClinVar, etc.) rather than reasoning from memory. A database-verified answer is always more reliable than a guess.

COMPUTE, DON'T DESCRIBE

When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.

When to Use This Skill

Triggers:

  • "Annotate variant [GENE]:[protein_change]" (e.g., "TP53:p.R175H")
  • "What is the functional impact of [variant]?"
  • "ProtVar annotation for [HGVS or rsID]"
  • "Population frequency of [variant]"
  • "Is [variant] in a conserved domain?"
  • "Structural context of [amino acid change]"

Pathogenicity Reasoning Framework

Assessing variant pathogenicity requires building a converging case from four independent evidence dimensions. No single metric is sufficient — concordance across dimensions defines confidence.

1. Conservation: Is the position evolutionarily constrained? If the residue has been maintained across vertebrates or all eukaryotes, mutation is likely to disrupt function. ProtVar's conservation score and GERP/PhastCons from OpenCRAVAT quantify this. High conservation at a position raises prior probability of pathogenicity, especially for missense variants. Low conservation suggests the position tolerates variation.

2. Location: Is it in a functionally critical region? A variant in an annotated active site or binding site is mechanistically impactful regardless of its frequency. Domain membership matters: a variant in the DNA-binding domain of a transcription factor is more concerning than one in an unstructured linker. Secondary structure context from ProtVar (helix, sheet, loop) adds resolution — loop residues are typically less constrained. Post-translational modification sites (phosphorylation, ubiquitination) are also critical positions.

3. Population frequency: Is it rare enough to be pathogenic? Highly penetrant pathogenic variants for rare diseases are almost always absent from population databases or present at very low frequency (gnomAD AF < 0.001). A variant present in 1% of the population is unlikely to cause a severe early-onset Mendelian disease. Note the max population AF (which ancestry has it highest) and the homozygote count — homozygotes in gnomAD argue against full penetrance for a recessive condition.

4. Computational prediction: Do algorithms agree? CADD PHRED ≥ 30 puts the variant in the top 0.1% most predicted-deleterious changes. REVEL ≥ 0.75 and AlphaMissense ≥ 0.564 indicate likely pathogenic predictions. When multiple tools agree, confidence in the computational signal increases; when they disagree, weight experimental evidence more heavily. CADD ≥ 20 supports the PP3 ACMG criterion; CADD < 10 supports BP4.

Synthesizing the four dimensions: A variant that is highly conserved, located in an active site, absent from gnomAD, and predicted deleterious by CADD and REVEL represents a strong pathogenicity signal even before looking at ClinVar. Conversely, a variant at a non-conserved position in a disordered region, present in 0.1% of the population, and predicted benign is unlikely pathogenic even if a ClinVar submitter once classified it as VUS. ClinVar classifications (especially multi-star entries from expert panels) override computational predictions; ClinGen gene-disease validity sets the context for interpreting any variant in that gene.


KEY PRINCIPLES

  1. ProtVar-first — ProtVar provides the richest protein-level context; always start here
  2. Notation flexibility — Accept HGVS (c./p.), genomic (chr:pos:ref:alt), rsID, or gene+AA change
  3. Population frequency mandatory — Always report gnomAD AF and note ancestry-specific values
  4. Structural context required for missense — Domain, active site, conservation
  5. Report-first approach — Create report file FIRST, update progressively
  6. Evidence grading mandatory — Grade all claims T1-T4

Evidence Grading

  • T1: ClinVar pathogenic with ≥3 submitters; ClinGen definitive gene-disease
  • T2: ClinVar pathogenic 1-2 submitters; CADD PHRED >25; functional studies cited
  • T3: Computational prediction (CADD 15-25, AlphaMissense, SIFT/PolyPhen); ProtVar structural flag
  • T4: Population frequency annotation only; domain membership annotation

Workflow Overview

Variant Input (HGVS / genomic / rsID / gene+protein_change)
|
+-- PHASE 0: Variant Notation Normalization
|   Resolve to canonical HGVS and UniProt position; confirm gene/transcript
|
+-- PHASE 1: ProtVar Protein-Level Annotation
|   map_variant -> structural coordinates, residue info, domain, active site
|   get_function -> conservation, functional impact prediction
|   get_population -> minor allele frequencies per ancestry
|
+-- PHASE 2: Population Frequency (gnomAD)
|   gnomad_get_variant -> AF global + ancestry-specific; homozygote count
|
+-- PHASE 3: Deleteriousness Scores (CADD)
|   CADD_get_variant_score -> PHRED score; raw C-score
|
+-- PHASE 3b: Multi-Source Annotation (OpenCRAVAT)
|   OpenCRAVAT_annotate_variant -> 182+ annotators in one call
|   (ClinVar, gnomAD, SIFT, PolyPhen-2, REVEL, AlphaMissense, SpliceAI, etc.)
|
+-- PHASE 4: Clinical Classification (ClinVar)
|   ClinVar_search_variants -> pathogenicity, review status, submitter count
|   ClinVar_get_variant_details -> full submission breakdown
|
+-- PHASE 5: Gene-Disease Validity (ClinGen)
|   ClinGen_search_gene_validity -> evidence classification for gene-disease pair
|
+-- SYNTHESIS: Integrated Annotation Report
    Structural context + population + deleteriousness + clinical + gene-disease

Phase 0: Variant Notation Normalization

Accepted input forms: HGVS coding (NM_000546.6:c.524G>A), HGVS protein (NP_000537.3:p.Arg175His), gene + protein change (TP53 R175H), genomic (chr17:7674220:G:A hg38), or rsID. Expand shorthand to full three-letter notation for ProtVar (e.g., "TP53 R175H" → "TP53 Arg175His").


Phase 1: ProtVar Protein-Level Annotation

ProtVar_map_variant takes hgvs, genomic (chr:pos:ref:alt), or protein_variant (GENE pAA#AA) — at least one is required. Extract accession (UniProt ID) and position from the result.

ProtVar_get_function(accession, position) returns conservation scores, domain membership, PTM sites, and functional impact annotations.

ProtVar_get_population(accession, position) returns gnomAD allele frequencies per ancestry from ProtVar's aggregation.

Key fields to reason over: active_site / binding_site flags are high-priority signals; conservation_score quantifies evolutionary constraint at this position; domain membership places the variant in biological context; secondary_structure (loop variants are typically less constrained than helix/sheet).


Phase 2: Population Frequency (gnomAD)

gnomad_get_variant takes variant_id in the format chrom-pos-ref-alt (hg38, no "chr" prefix). Always report the global AF, the maximum population-specific AF, and the homozygote count. Use gnomad_search_variants as fallback when the exact variant ID is not known.

Absence from gnomAD is noteworthy but does not independently establish pathogenicity.


Phase 3: Deleteriousness Scores (CADD)

CADD_get_variant_score takes chrom (without "chr" prefix), pos, ref, alt, genome (default "GRCh38"). CADD PHRED ≥ 30 is top 0.1% most deleterious; ≥ 20 is top 1-10%. Use OpenCRAVAT_annotate_variant with annotators="cadd_exome" as fallback if CADD is unavailable.


Phase 3b: Multi-Source Annotation (OpenCRAVAT)

OpenCRAVAT_annotate_variant takes chrom, pos (1-based GRCh38), ref_base, alt_base, and an optional comma-separated annotators string. The chrom parameter auto-adds the "chr" prefix if missing.

For missense variants, use annotators "clinvar,gnomad3,sift,polyphen2,revel,alphamissense,cadd_exome". For splice-region variants, add "spliceai,dbscsnv". For non-coding variants, add "gerp,phastcons,dann".

When scores disagree: If REVEL says benign but CADD says deleterious, weight REVEL more heavily for missense (it is specifically trained on missense). If multiple tools agree, the signal is more reliable. Document the concordance pattern in the report.


Phase 4: Clinical Classification (ClinVar)

ClinVar_search_variants(query="GENE protein_change") returns pathogenicity classifications and review status. ClinVar_get_variant_details(variant_id) provides the full submission breakdown.

ClinVar review status (star ratings): 4 stars = practice guideline (highest confidence); 3 = expert panel reviewed; 2 = multiple submitters without conflict; 1 = single submitter; 0 = conflicting or not reviewed. Single-submitter VUS classifications carry limited weight; expert panel classifications override computational predictions.

If ClinVar is unavailable, use OpenCRAVAT_annotate_variant with annotators="clinvar" as a fallback.


Phase 5: Gene-Disease Validity (ClinGen)

ClinGen_search_gene_validity(gene_symbol, disease_label) returns curated gene-disease evidence classifications. ClinGen classifications from strongest to weakest: Definitive → Strong → Moderate → Limited → Disputed → Refuted.

Critical reasoning step: If the gene-disease relationship is Disputed or Refuted, any pathogenic ClinVar variant in this gene must be interpreted with extreme caution — the clinical relevance is uncertain independent of variant-level evidence. Always report ClinGen classification before interpreting variant pathogenicity.


Synthesis: Integrated Annotation Report

# Variant Functional Annotation: [GENE] [VARIANT]
**Generated**: YYYY-MM-DD
**Input**: [original user input]
**Canonical notation**: [HGVS c. and p.]

## Executive Summary
(2-3 sentences: structural context, population frequency, pathogenicity signal)

## 1. Variant Identity
(Canonical HGVS, gene, transcript, consequence type, amino acid change)

## 2. Protein Structural Context [T3-T4]
(From ProtVar: domain, secondary structure, active/binding site, 3D coordinates)

## 3. Functional Annotations [T3]
(Conservation, predicted impact, PTM proximity, domain function)

## 4. Population Frequency [T4]
(gnomAD global AF, max population AF, homozygote count)

## 5. Deleteriousness Score [T3]
(CADD PHRED, REVEL, AlphaMissense — note concordance or discordance)

## 6. Clinical Classification [T1-T2]
(ClinVar significance, review stars, submitter count)

## 7. Gene-Disease Validity [T1]
(ClinGen classification for relevant disease)

## 8. Integrated Assessment
(Reasoning across all four dimensions: conservation, location, frequency, prediction)

## Data Gaps
(Any phase with no data; confidence caveats)

Fallback Chains

  • ProtVar_map_variant fails → try with genomic notation or protein_variant format
  • gnomad_get_variant fails → use gnomad_search_variants by gene, or OpenCRAVAT gnomad3 annotator
  • CADD_get_variant_score unavailable → use OpenCRAVAT cadd_exome annotator
  • ClinVar_search_variants returns empty → use OpenCRAVAT clinvar annotator
  • ClinGen_search_gene_validity returns no data → note gene-disease relationship not curated by ClinGen

Limitations

  • ProtVar: Covers UniProt canonical isoforms only; alternative isoforms not mapped
  • gnomAD: Based on gnomAD v4 (exomes + genomes); mitochondrial variants have separate AF
  • CADD: Computational prediction only [T3]; does not replace experimental evidence
  • ClinVar: Reflects submitter interpretations; star rating reflects concordance not accuracy
  • ProtVar structural coordinates: Derived from AlphaFold2 where no experimental structure exists

适合场景

01

用户想查找某类 Agent Skill 时

02

需要根据任务场景推荐可安装能力包时

03

需要对比不同来源的安装命令和来源信息时

能力概览

能力 1

按任务关键词查找相关 Skills

能力 2

展示可复制的安装命令

能力 3

保留来源站点、仓库和原始说明,方便继续核验

能力 4

展示第三方安全扫描或审计结果

安装后应在对应宿主中按原始 README 的触发条件使用;具体调用方式请以来源页面和 README 为准。

平台分布

Codex

34.83%
按下载量换算124

Claude

29.61%
按下载量换算105

Cursor

16.7%
按下载量换算59

Gemini CLI

9.73%
按下载量换算35

安全审计

Gen Agent Trust Hub

通过

Socket

通过

Snyk

可疑

权限和风险

权限需确认

当前来源未能明确判断权限范围,默认进入异常复核队列。

安装前确认

本站仅展示第三方公开信息,不托管安装包,不提供自动安装或运行环境。安装前应自行审查源码、依赖和命令行为。来源安全扫描存在 warning/failed 结果,不能写成本站确认安全。当前只有一个来源,正式发布前建议补源仓库或其他目录站核验。

来源信息

继续浏览同类 Skills